Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia
Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia
复制标题
DOI：
10.1038/eye.2010.61
复制
发表时间：
2010-09-01
期刊：
影响因子：
3.9
通讯作者：
Yoshimura, N.
中科院分区：
文献类型：
--
作者：
Takayama, K.;Ooto, S.;Yoshimura, N.
目的评价玻璃体内注射贝伐单抗治疗1型特发性黄斑毛细血管扩张症(IMT)的疗效。方法对5例5眼男性1型IMT患者玻璃体腔内注射贝伐单抗2~3只眼的病例进行回顾性分析。结果术后随访12~21个月，平均17.0个月。用药后3个月和12个月时最小分辨视力的平均对数分别为0.295和0.254(P=0.194)和0.311(P=0.461)。术后12个月，1只眼视力提高，3只眼保持稳定，1只眼视力下降。治疗前平均黄斑中心凹厚度为479微米；在治疗后1个月，只有一只眼黄斑水肿明显减轻。用药后3个月和12个月的平均中心凹厚度分别为418um(P=0.287)和473um(P=0.482)。12个月时，1眼黄斑中心凹厚度减少100微米，2眼黄斑中心凹厚度增加100微米。结论玻璃体腔内注射贝伐单抗并不能改善1型IMT患者的视力或视网膜水肿。Eye(2010)24,1492年-1497年；doi：10.1038/ye.2010.61；2010年4月30日在线发布
Purpose To evaluate the effect of intravitreal bevacizumab injection for treating type 1 idiopathic macular telangiectasia (IMT).Methods Retrospective case series of five eyes of five male patients with type 1 IMT that were treated with 2-3 injections of intravitreal bevacizumab. Best-corrected visual acuity, foveal thickness obtained by optical coherence tomography, and fluorescein angiography (FA) were monitored over a period of up to 12 months.Results The average follow-up period was 17.0 months (range, 12-21 months). The mean logarithm of the minimal angle of resolution visual acuity was 0.295 at baseline and 0.254 (P=0.194) and 0.311 (P=0.461) at 3 and 12 months, respectively, after the initial injection. At 12 months, visual acuity had improved in one eye, remained stable in three eyes, and decreased in one eye. The mean foveal thickness was 479 mu m at baseline; at 1 month after the therapy, marked reduction of macular oedema was seen only in one eye. The mean foveal thickness was 418 mu m (P=0.287) and 473 mu m (P=0.482) at 3 and 12 months after the initial injection, respectively. At 12 months, the foveal thickness had decreased by >100 mu m in one eye, but had increased by >100 mu m in two eyes. FA did not show a reduction in late leakage.Conclusions Treatment with intravitreal bevacizumab does not appear to improve visual acuity or retinal oedema in type 1 IMT. Eye (2010) 24, 1492-1497; doi:10.1038/eye.2010.61; published online 30 April 2010